Correlation of Geboes score with long-term clinical outcomes
GS
SECONDARY, REMISSION
The relationship between the Geboes score and long-term clinical outcomes was also evaluated. Patients were assigned to the following Geboes score intervals [0, 2.0), [2.0, 3.1], and (3.1, 5.4] based on the histologic evaluation of biopsy samples taken during the U-ACHIEVE maintenance trial. These intervals were selected to assess patients who achieved the histology threshold for mucosal healing (Geboes score < 2.0) and those who achieved the histologic mucosal improvement threshold without mucosal healing [2.0, 3.1]. Patients with GS < 2.0 at Week 52 had significantly greater odds of achieving all clinical endpoints at Week 52 compared to patients with GS > 3.1 (Supplemental Fig. 1). Patients with GS < 2.0 at end of induction had a significantly higher likelihood of achieving clinical remission per adapted Mayo score (OR = 1.8, In addition, we calculated Spearman correlations for the Geboes score and secondary measures at baseline and Week 8 (end of induction). At Week 8, moderate (